Pacira | PCRX - Operating Expenses


Pacira reported $166.36M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Astellas Pharma JPY 419.91B 6.66B Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 18.97B 2.38B Dec/2025
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
Novo Nordisk DKK 42.77B 3.48B Jun/2025
Pacira USD 166.36M 4.5M Sep/2025
Perrigo USD 949.9M 50.8M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Supernus Pharmaceuticals USD 252.29M 98.98M Sep/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
Xeris Pharmaceuticals USD 67.65M 590K Sep/2025
Zoetis USD 5.4B 3.94B Sep/2025